July 23, 2026
Biotechnology company Sangamo Therapeutics received interim approval Thursday to tap into a new, $35 million Chapter 11 financing package with a lower interest rate.
July 22, 2026
Sangamo Therapeutics on Wednesday told a Delaware bankruptcy judge it has negotiated new Chapter 11 financing that will provide the biotechnology company with more money at a lower interest rate and asked permission to take out the new loan.
June 30, 2026
A team of lawyers from Richards Layton & Finger PA and Cooley LLP is representing life sciences group Sangamo Therapeutics Inc. in a recently filed Chapter 11 case as the company looks to sell parts of its business to Eli Lilly & Co. and Astellas Pharma Inc.
June 24, 2026
A Delaware bankruptcy judge on Wednesday granted interim approval of a $30 million Chapter 11 financing package for biotechnology company Sangamo Therapeutics Inc., funds that the debtor will use to support a sale process for its assets.
June 23, 2026
Insurance company Hallmark Financial Services filed for Chapter 11 looking to cut nearly $134 million in debt via a sale or equity swap, an investment management firm specializing in medical spas and medical aesthetics providers entered Chapter 11 in Delaware with over $10 million in debt, and a Tex-Mex chain operator began liquidation in the Lone Star State.
June 23, 2026
Sangamo Therapeutics Inc. filed for bankruptcy protection in Delaware on Tuesday with offers to sell parts of its genetic therapy development programs to Eli Lilly and Co. and Astellas Pharma Inc.